Path: /therapeutics/huntington-disease-treatment
Title: Huntington's Disease Treatment
Tags: section:treatments, kind:treatment
| Huntington's Disease Treatment |
|---|
| Disease | [Huntington's Disease](/diseases/huntingtons) |
| Target | Mutant huntingtin protein (mHTT) |
| Treatment Types | Symptomatic, Disease-modifying, Emerging |
| Approved Therapies | Tetrabenazine, Deutetrabenazine, Valbenazine |
| Clinical Trials | Gene silencing, ASOs, Immunotherapies |
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG trinucleotide repeat expansion in the HTT gene, resulting in a mutant huntingtin protein (mHTT) with toxic gain-of-function[@the1993]. The disease manifests with progressive motor, cognitive, and psychiatric symptoms, typically onsetting in middle age. Treatment approaches encompass symptomatic management, disease-modifying therapies targeting mHTT reduction or clearance, and emerging gene-targeted interventions[@ross2014].
Chorea (involuntary dance-like movements) is the hallmark motor manifestation:
-
Tetrabenazine (Xenazine): First FDA-approved drug for chorea in HD. VMAT2 inhibitor depletes dopamine from presynaptic vesicles[@huntington2006].
- Dose: 12.5-100 mg/day divided TID
- Monitor: Depression, suicidal ideation, parkinsonism
- Contraindications: Depression, suicidal ideation, parkinsonism
-
Deutetrabenazine (Austedo): Deuterated analogue with improved pharmacokinetics and tolerability[@huntington2017].
- Dose: 6-48 mg/day divided BID
- Advantages: Lower risk of depression and sedation vs tetrabenazine
- FDA approved for HD chorea (2017)
-
Valbenazine (Ingrezza): VMAT2 inhibitor with once-daily dosing[@factor2020].
- Dose: 40-80 mg once daily
- Advantages: Well-tolerated, once-daily dosing
- FDA approved for tardive dyskinesia, being studied for HD
-
Haloperidol: Traditional choice for chorea and behavioral symptoms[@shen2022].
- Dose: 1-10 mg/day
- Side effects: Extrapyramidal symptoms, sedation, hyperprolactinemia
-
Olanzapine: Atypical antipsychotic with dopamine blockade and mood stabilization[@paleacu2003].
- Dose: 2.5-20 mg/day
- Advantages: Less EPS than haloperidol, helps psychiatric symptoms
-
Aripiprazole: Partial dopamine agonist with favorable side effect profile[@anderson2008].
- Dose: 2-15 mg/day
- Advantages: Lower risk of tardive dyskinesia
No FDA-approved treatments for HD cognitive decline. Strategies include:
- Cognitive rehabilitation: Structured cognitive training programs[@craufurd2001]
- Environmental modifications: Simplify tasks, use reminders, establish routines
- Assistive devices: calendars, alarms, organized living spaces
- Caregiver support: Education and training for daily management
-
Selective serotonin reuptake inhibitors (SSRIs): First-line for depression in HD[@anderson2013].
- Escitalopram: 10-20 mg/day
- Sertraline: 50-200 mg/day
- Citalopram: 20-40 mg/day
-
Mirtazapine: Noradrenergic and specific serotonergic antidepressant, also helps sleep/anxiety[@huntington2015].
- Dose: 15-45 mg at bedtime
-
Electroconvulsive therapy (ECT): For severe, treatment-resistant depression[@mendez1996]
- Atypical antipsychotics: Risperidone, olanzapine, quetiapine[@sadock2009]
- Clozapine: For refractory cases, requires ANC monitoring
ASOs bind to mHTT mRNA and promote RNase H-mediated degradation:
-
Tominersen (RG6042): Huntingtin-lowering ASO administered intrathecally[@biogen2024].
- Phase III GENERATION HD1 trial (2019-2021)
- Results: Did not meet primary endpoint, development discontinued
- Lessons: Need for earlier intervention, biomarker optimization
-
ASO-HTT Rx: Ionis/Roche ASO targeting all HTT transcripts[@tabrizi2019].
- Phase I/II trials completed
- Showed dose-dependent HTT reduction in CSF
-
WVE-003 (Wave Life Sciences): Single-stranded ASO targeting mutant allele with SNP3[@wave2024].
- Phase Ib/IIa trial ongoing
- Selectively reduces mHTT while preserving wild-type
- ** AAV-delivered microRNA:** Intraparenchymal delivery to striatum[@drouet2009].
- Preclinical: Successful HTT lowering in animal models
- Challenges: Delivery, durability, immune response
- Curcumin and derivatives: Natural compound shown to reduce mHTT aggregation[@wang2008].
- Clinical trials: Limited by bioavailability
- Research: Nanoformulations in development
- Autophagy inducers: Rapamycin, trehalose enhance mHTT clearance[@sarkar2007].
- UPS modulators: Enhance mutant protein degradation
- Sodium butyrate, valproic acid: Modulate transcription, show neuroprotective effects[@steffan2001].
- 4b (HDACi): Specific HDACi in preclinical development
-
CoQ10 (Ubiquinone): Antioxidant and mitochondrial support[@huntington2001].
- Phase III trial (2CARE): Negative results
- Continue: May benefit specific subgroups
- Dose: 600-2400 mg/day
-
Creatine: Supports cellular energy, shown safe in HD[@verbessem2003].
- PRECREST trial: Mixed results, better in earlier disease
-
Eicosapentaenoic acid (EPA): Omega-3 fatty acid, anti-inflammatory[@puri2004].
-
Minocycline: Antibiotic with anti-inflammatory properties[@thomas2004].
- Clinical trials: Mixed results
- Concern: Potential side effects with long-term use
-
Natalizumab: Anti-α4 integrin antibody, being studied[@curnow2020].
-
CRISPR/Cas9: Direct editing of mutant HTT gene[@zeitlin2015].
- Challenges: Delivery to CNS, off-target effects
- Status: Preclinical
-
Base editing: More precise than CRISPR, single-nucleotide correction[@liu2020].
- Lithium: Mood stabilizer with neuroprotective properties[@chiu2011].
- Ambroxol: Enhances lysosomal function, increases GAG clearance[@maglioni2020].
- Metformin: AMPK activator, being studied in HD[@jalencas2019].
-
Exercise: Regular aerobic exercise improves motor function and may slow progression[@quinn2014].
- Recommended: 150 minutes/week moderate activity
- Types: Walking, swimming, cycling
-
Balance training: Reduce fall risk[@kloos2009].
-
Speech therapy: For dysarthria and swallowing difficulties[@enderby2004].
- Home modifications: Safety improvements, assistive devices[@nance2004].
- Energy conservation techniques: Manage fatigue.
- Adaptive equipment: For daily activities.
¶ Speech and Swallowing
- Speech therapy: Maintain communication abilities[@rusz2015].
- Dysphagia management: Positioning, food modifications, swallowing techniques.
- FEES/VS: Evaluate swallowing function.
- Caloric supplementation: Prevent weight loss[@djouss2003].
- High-calorie diet: May improve motor function (some studies).
- Hydration: Maintain adequate fluid intake.
- Feeding tubes: For advanced disease (PEG tubes).
- GENERATION HD1 (Tominersen): Completed, negative results[@biogen2024].
- HD-CAS (GeneSite): CRISPR-based approach.
- SELECT-HD (Wave Life Sciences): WVE-003 SNP3-selective ASO[@wave2024].
- AMTOR (Prana Biotechnology): PBT2 metal protein attenuation.
- Biomarkers: CSF HTT, neuroimaging, digital health measures
- Outcome measures: UHDRS, TFC, cognitive assessments
- Patient selection: Premanifest vs manifest, age, CAG length
flowchart TD
A["HD Diagnosis"] --> B{"Primary Symptoms"}
B --> C["Chorea"]
B --> D["Depression"]
B --> E["Irritability"]
B --> F["Cognitive Decline"]
C --> C1["Tetrabenazine"]
C --> C2["Deutetrabenazine"]
C --> C3["Valbenazine"]
C --> C4["Antipsychotics"]
D --> D1["SSRIs"]
D --> D2["Mirtazapine"]
D --> D3["ECT"]
E --> E1["Mood Stabilizers"]
E --> E2["Antipsychotics"]
F --> F1["Cognitive Rehab"]
F --> F2["Environment Modifications"]
F --> F3["Caregiver Support"]
G["Disease-Modifying"] --> G1["ASOs - Clinical Trials"]
G --> G2["Gene Therapy - Investigational"]
G --> G3["Neuroprotective - Investigational"]
- The Huntington's Disease Collaborative Research Project, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes (1993)
- Ross CA, et al, Huntington disease: molecular mechanisms of disease and therapeutic strategies (2014)
- Huntington Study Group, Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial (2006)
- Huntington Study Group, Deutetrabenazine for chorea in Huntington disease (2017)
- Factor SM, et al, Valbenazine for the treatment of chorea in Huntington's disease (2020)
- Shen J, et al, Pharmacological management of Huntington's disease: an updated review (2022)
- Paleacu D, et al, Olanzapine in Huntington's disease (2003)
- Anderson KE, et al, Aripiprazole for the treatment of Huntington's disease (2008)
- Craufurd D, et al, Cognitive decline and progression in Huntington disease (2001)
- Anderson KE, Psychiatric complications in Huntington's disease (2013)
- Huntington Study Group, A randomized, double-blind, placebo-controlled study of mirtazapine for depression in Huntington's disease (2015)
- Mendez MF, Electroconvulsive therapy in Huntington's disease (1996)
- Sadock BJ, Sadock VA, Kaplan & Sadock's Comprehensive Textbook of Psychiatry (2009)
- Biogen, Update on Tominersen program (2024)
- Tabrizi SJ, et al, Targeting huntingtin expression in patients with Huntington's disease (2019)
- Wave Life Sciences, SELECT-HD Trial (2024)
- Drouet V, et al, RNA interference-based therapy for Huntington's disease using AAV-delivered microRNA (2009)
- Wang J, et al, Curcumin reduces mutant huntingtin protein expression in cell and mouse models (2008)
- Sarkar S, et al, Small molecule enhancers of autophagy for neurodegenerative diseases (2007)
- Steffan JS, et al, Histone deacetylase inhibitors as a therapeutic approach to Huntington's disease (2001)
- Huntington Study Group, A randomized, double-blind, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease (2001)
- Verbessem P, et al, Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial (2003)
- Puri BK, et al, Eicosapentaenoic acid supplementation in Huntington's disease (2004)
- Thomas M, et al, Minocycline in Huntington's disease: a randomized, double-blind, placebo-controlled trial (2004)
- Curnow J, et al, Immunotherapy for Huntington's disease (2020)
- Bachoud-Lévi AC, et al, Neural grafts in Huntington's disease: 10 years of the multicentre intracerebral transplantation network (2009)
- Zhang N, et al, Stem cell therapy for Huntington's disease: a mini-review (2017)
- Zeitlin SO, et al, CRISPR/Cas9 editing of mutant huntingtin in mice (2015)
- Liu G, et al, Base editing: a new approach to correct Huntington's disease-causing mutations (2020)
- Baldo B, et al, An approach to immunotherapy for Huntington's disease (2015)
- Miller TW, et al, A vaccine for Huntington's disease (2003)
- Chiu CT, et al, Therapeutic benefits of lithium: from brain disorders to brain diseases (2011)
- Maglioni S, et al, Repurposing drugs for rare neurodegenerative diseases: from preclinical studies to clinical trials (2020)
- Jalencas V, et al, Metformin as a potential disease-modifying therapy in Huntington's disease (2019)
- Quinn L, et al, Exercise for people with Huntington's disease: a systematic review (2014)
- Kloos AD, et al, Balance and gait in Huntington's disease (2009)
- Enderby P, Speech and language therapy for Huntington's disease (2004)
- Nance M, et al, Occupational therapy for Huntington's disease (2004)
- Rusz J, et al, Speech disorders in Huntington's disease (2015)
- Djoussé L, et al, Weight loss in Huntington disease (2003)